12 new abstracts support the use of LUCAS at the ERC meeting in Ghent
Lund, Sweden, 24th of September, 2008
Twelve new abstracts presented at the major European resuscitation congress support the safety and efficacy of the LUCAS Chest Compression System. The abstracts, from researchers in five countries, constitute the biggest backing of LUCAS presented in one place to date.
The European Resuscitation Council’s 2008 Congress, held in Ghent, Belgium, in May, is another important step forward for LUCAS, which performs continuous chest compressions to maintain the blood flow to the brain and heart in cardiac arrest patients. The growing body of evidence all points in one direction; that LUCAS increases and maintains blood flow, is safe for the patient, increases safety for the medical personnel, prolongs the window of rescue, and creates new rescue opportunities. Study after study shows that survival rates and quality of survival are equal or improved with LUCAS uninterrupted and consistent compressions.
The new abstracts supporting the LUCAS Chest Compression System came from several countries around Europe; Germany, Belgium, Ireland, Austria and Sweden.
“These positive abstracts shows how several ambulance systems and hospitals around Europe have successfully implemented the LUCAS Chest Compression System and with that secured the quality of CPR which is the foundation of resuscitation.” said Erik von Schenck, CEO of JOLIFE.
The abstracts can be found under clinical references at www.lucas-cpr.com.
About LUCAS™ CPR
The LUCAS™ chest compression system helps ambulance and hospital personnel to save patients suffering from sudden cardiac arrest. The device performs continuous chest compressions to maintain the blood flow to the brain and heart. International resuscitation guidelines issued in 2005 stress the importance of effective and uninterrupted chest compressions before defibrillation. LUCAS performs chest compressions in accordance with these guidelines without risking variations in quality or tiring out personnel. The device also allows safe transportation and permits simultaneous defibrillation and angiography.
About Jolife AB
Jolife is dedicated to increasing the survival of people suffering from sudden cardiac arrest, and increasing the number who survive with their quality of life intact. This is being achieved by leading research and development in the field in order to offer innovative products which define the future for the treatment of sudden cardiac arrest. The company was founded in 2000 and has since worked closely with leading physicians and paramedics on research and development. This work has led to groundbreaking knowledge about the physiological effects of cardiac arrest and the importance of high-quality chest compressions. The LUCAS chest compression system is available for sale in the USA, Europe and other parts of the world. Based in Lund in southern Sweden, Jolife markets its products through an exclusive global distribution agreement with Physio-Control, Inc. – a division within Medtronic Ltd., except in Sweden, Norway and Finland where it sells direct. For further information, please visit www.jolife.com or www.lucas-cpr.com